E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« Supreme Court Preview -- Sandoz Inc. v. Amgen Inc. | Main | Supreme Court Hears Oral Argument in Sandoz v. Amgen -- Patent Dancing and Missing Puzzle Pieces »

April 25, 2017

Comments

Hey Kevin,

Sigh. Why am I not surprised that we've got an interpretational "mess" when it comes to the biosimilar provisions (e.g., "patent dance") of the ACA (aka "Obamacare")? The ACA itself is an utter mess, so that the biosimilar provisions are too is completely predictable. And I've got no confidence that SCOTUS will do any better than the Federal Circuit did in trying to render order out of this biosimilar chaos.

The comments to this entry are closed.

November 2017

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30